Literature DB >> 8723468

Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.

G V Doern1, A Brueggemann, H P Holley, A M Rauch.   

Abstract

A total of 1,527 clinically significant outpatient isolates of Streptococcus pneumoniae were prospectively collected in 30 different U.S. medical centers between November 1994 and April 1995. Overall, 23.6% of strains were not susceptible to penicillin, with 14.1% intermediate and 9.5% high-level resistant. The frequencies of recovery of intermediate and high-level resistant strains varied considerably between different medical centers and in different geographic areas. In general, intermediate and high-level penicillin resistance was most common with isolates of S. pneumoniae recovered from pediatric patients. The in vitro activities of 22 other antimicrobial agents were assessed against this collection of isolates. Ampicillin was consistently 1 twofold dilution less active than penicillin. Amoxicillin and amoxicillin-clavulanate were essentially equivalent to penicillin in activity. The rank order of activity for cephalosporins was cefotaxime = ceftriaxone > or = cefpodoxime > or = cefuroxime > cefprozil > or = cefixime > cefaclor = loracarbef > cefadroxil = cephalexin. The National Committee for Clinical Laboratory Standards [Performance Standards for Antimicrobial Susceptibility Testing, Sixth Information Supplement (M100-S6), 1995] has established MIC breakpoints for resistance (i.e., > or = 2 micrograms/ml) with three cephalosporins versus S. pneumoniae, namely, cefotaxime, ceftriaxone, and cefuroxime. The overall percentages of strains resistant to these three antimicrobial agents were 3, 5, and 12, respectively. The overall frequency of resistance was 10% with all three macrolides examined in this study, clarithromycin, erythromycin, and azithromycin. The overall percentages of chloramphenicol, tetracycline, and trimethoprim-sulfamethoxazole resistance were 4.3, 7.5, and 18, respectively. The resistance percentages among the cephalosporins, macrolides, chloramphenicol, tetracycline, and trimethoprim-sulfamethoxazole were consistently higher among penicillin-intermediate strains than among susceptible isolates and even higher still among organisms expressing high-level penicillin resistance. Multiply resistant strains represented 9.1% of the organisms examined in this study. Finally, rifampin resistance was uncommon (i.e., 0.5%), and vancomycin resistance was not detected. The quinopristin-dalfopristin combination was consistently active at concentrations of 0.25 to 4 micrograms/ml, but rates of resistance could not be determined in the absence of established interpretive criteria for MIC results.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723468      PMCID: PMC163293          DOI: 10.1128/AAC.40.5.1208

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone.

Authors:  A M Figueiredo; J D Connor; A Severin; M V Vaz Pato; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group.

Authors:  J S Spika; R R Facklam; B D Plikaytis; M J Oxtoby
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

3.  Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics.

Authors:  J S Bradley; J D Connor
Journal:  Pediatr Infect Dis J       Date:  1991-11       Impact factor: 2.129

4.  Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci.

Authors:  Z Markiewicz; A Tomasz
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

Review 5.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

6.  Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.

Authors:  J H Jorgensen; G V Doern; L A Maher; A W Howell; J S Redding
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 7.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

8.  Five independent combinations of mutations can result in low-affinity penicillin-binding protein 2x of Streptococcus pneumoniae.

Authors:  G Laible; R Hakenbeck
Journal:  J Bacteriol       Date:  1991-11       Impact factor: 3.490

9.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

10.  Susceptibility of relatively penicillin-resistant Streptococcus pneumoniae to newer cephalosporin antibiotics.

Authors:  G S Bosley; J A Elliott; M J Oxtoby; R R Facklam
Journal:  Diagn Microbiol Infect Dis       Date:  1987-05       Impact factor: 2.803

View more
  103 in total

1.  Two-year surveillance of antibiotic resistance in Streptococcus pneumoniae in four African cities.

Authors:  M Benbachir; S Benredjeb; C S Boye; M Dosso; H Belabbes; A Kamoun; O Kaire; N Elmdaghri
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa.

Authors:  L McGee; K P Klugman; A Wasas; T Capper; A Brink
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria.

Authors:  S K Spangler; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

4.  Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.

Authors:  T A Davies; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

5.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

6.  Use of an oxacillin disk screening test for detection of penicillin- and ceftriaxone-resistant pneumococci.

Authors:  L P Jetté; C Sinave
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

7.  Antibiotic resistance: the Bermuda experience.

Authors:  S Smith; R C Tilton
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

8.  Emergence in france of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin.

Authors:  C Doit; C Loukil; F Fitoussi; P Geslin; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

9.  Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Authors:  E A Coyle; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 10.  Management of acute otitis media in the 1990s: the decade of resistant pneumococcus.

Authors:  S L Block
Journal:  Paediatr Drugs       Date:  1999 Jan-Mar       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.